Replies to post #643 on Matinas Biopharma Holdings Inc (MTNB)

[XenaLives]

Informative Excerpt:

A UNIQUE APPROACH: COCHLEATE LIPID-CRYSTAL NANOPARTICLE- TARGETED DRUG DELIVERY TECHNOLOGY

Unique approaches to treating these diseases that may provide effective antifungal treatment while minimizing severe toxicities include the development of such agents in unique formulations. Matinas BioPharma, a clinical-stage biopharmaceutical company focused on identifying and developing anti-fungal and anti-bacterial therapeutics for life-threatening infections, is currently testing its most advanced product, MAT2203, an orally administered, encochleated formulation of the broad-spectrum antifungal medication amphotericin B (AmB) for the treatment of serious and life-threatening fungal infections.

https://drug-dev.com/delivery-platform-encochleated-drug-formulations-enhancing-efficacy-minimizing-toxicity/